 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2022, vol. 28, issue4
Subject Area: Medicine
-
DOI: 10.5272/jimab.2022284.4735
Published online: 14 December 2022
Original article
J of IMAB. 2022 Oct-Dec;28(4):4735-4737
MORBIDITY AND MORTALITY FROM COVID-19 IN A DIALYSIS CENTER IN NORTHERN BULGARIA
Biser Borisov1
, Elena Borisova2, Desislava Lubomirova3, Pavlina Glogovska2,
1) Department of Nephrology and Dialysis, Faculty of Medicine, Medical University, Pleven, Bulgaria.
2) Department of Pulmonology and Phtisiology, Faculty of Medicine, Medical University, Pleven, Bulgaria.
3) Department of Gastroenterology, Faculty of Pharmacy, Medical University, Pleven, Bulgaria.
ABSTRACT:
Purpose: Since its inception in early 2020, COVID-19 has quickly become a pandemic, killing more than six million people worldwide. The aim of this study is to investigate the morbidity and mortality of COVID-19 in one Bulgarian hemodialysis center.
Materials and methods: The study is retrospective, conducted for the period of 25th Apr 2020 – 31st Dec 2021. The mean annual number of hemodialysis patients was 184, including patients with end-stage renal disease and acute renal failure. The total number of patients with COVID-19 was 78 (42%), 49of which (63%) were males, the average age was 60 years (+/-12.1 years).
Results: There was no significant difference between the mean age of patients divided by sex (p=0.069). A total of 33 people died (42%), 17 of whom (51%) were males. The average age of the deceased patients (64.24 +/- 10.846) was higher than that of the survivors (58.44 +/-12.286), and the difference was significant (p=0.034). There was no significant difference in the mean age of survived and deceased males (p=0.74) but for females, the difference was statistically significant – the mean age of survivorswas 55.00 (+/-12.03)and of the deceased patients was 67.6 (+/- 8.79) years.
Conclusion: Our results confirm data from similar studies aboutthe high incidence and mortality of COVID-19 in hemodialysis patients. We confirma statistically significant increase in mortality of these patients with increasing age. Probably the mass vaccination of patients and staff; the use of antiviral drugs and biological therapy is the way to reduce morbidity and mortality among them.
Keywords: end-stage renal disease, hemodialysis, COVID-19 - morbidity and mortality,
- Download FULL TEXT /PDF 551 KB/
Please cite this article as: Borisov B, Borisova E, Lubomirova D, Glogovska P. Morbidity and Mortality from COVID-19 in a Dialysis Center in Northern Bulgaria. J of IMAB. 2022 Oct-Dec;28(4):4735-4737. DOI: 10.5272/jimab.2022284.4735
Correspondence to: Biser Borisov, MD. PhD., Department of Nephrology and Dialysis, Faculty of Medicine, Medical University, Pleven; 8A, George Kochev Str., Pleven 5800, Bulgaria; E-mail: biserugo@abv.bg
REFERENCES:
1. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of Immune Dysfunction in End-stage Renal Disease. Clin J Am SocNephrol. 2008 Sep;3(5):1526-33. [PubMed]
2. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193-292. [PubMed]
3.Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. MethodsMolBiol. 2015; 1282:1-23. [PubMed]
4. Almeida JD, Berry DM, Cunningham CH, Hamre D, Hofsted MS, Mallucci L, et al. Coronaviruses. Nature. 1968;220(5168):650. [PMC]
5. Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J. 2005Nov;24(11 Suppl):S223-7. [PubMed]
6. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936. [PubMed]
7. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020 Jun 1;49(3):717-726. [PubMed]
8.Hussain A, Kaler J, Tabrez E, Tabrez S, Tabrez SSM. Novel COVID-19: a comprehensive review of transmission, manifestation, and pathogenesis. Cureus. 2020 May 18;12(5):e8184. [PubMed]
9. Coronavirus Death Toll. Worldometer. [Internet]
10. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020 Dec;98(6):1530-1539. [PubMed]
11. Scarpioni R, Manini A, Valsania T, De Amicis SD, Albertazzi V, Melfa L, et al. Covid-19 and its impact on nephropathic patients: the experience at Ospedale "Guglielmo da Saliceto" in Piacenza. G Ital Nefrol.2020 Apr 9;37(2):2020-vol2. [PubMed]
12. Turgutalp K, Osturk S, Arici M, Eren N, Gorgulu N, Islam M, et al. Determinants of mortality in a large group of hemodialysis patients hospitalized for COVID-19. BMC Nephrology. 2021 Jan 14;22(1):29. [PubMed]
13. Goicoechea M, Sánchez Cámara LA, Macías N, Morales AM, RojasAG, BascuñanaA, etal. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney Int. 2020 Jul;98(1):27-34. [PubMed]
Received: 04 July 2022
Published online: 14 December 2022